The response of Intravenous Iron sucrose in children with Iron Deficiency Anaemia unresponsive to Oral Iron Therapy.

Abstract

Objective: To evaluates the efficacy and safety of intravenous iron sucrose in paediatric patients with IDA who have not responded to or tolerated oral iron therapy.
Methodology: This observational study was conducted at Department of Paediatrics, Pakistan aeronautical complex (PAC) Hospital Kamra, from October 2023 to April 2024. Iron sucrose (Venofer®) was administered at a dose of 0.35 ml/kg, providing 100 to 200 mg of elemental iron per dose, on alternate days for three doses. Haemoglobin (Hb) and serum ferritin levels were measured 4 weeks post-treatment to evaluate response.
Results: Among the participants, 70 (70%) were male and 30 (30%) were female, with a mean age of 34.23 ±19.54 months. Results showed a significant increase in mean Hb from 7.92 ± 0.74 g/dl before treatment to 10.46 ± 0.94 g/dl after treatment (p = 0.001)
Conclusion: Clinicians should consider intravenous iron therapy to enhance patient outcomes, improve quality of life, and potentially reduce healthcare costs.

Keywords: Iron Deficiency Anaemia (IDA), Anaemia, Haemoglobin (Hb), Oral Iron, Intravenous Iron.